A rationally designed anticancer drug targeting a unique binding cavity of tubulin.

Basic Information

ID: ALA1132867

Journal: Bioorg Med Chem Lett

Title: A rationally designed anticancer drug targeting a unique binding cavity of tubulin.

Authors: Uckun FM, Mao C, Vassilev AO, Navara CS, Narla RK, Jan ST.

Abstract: A novel mono-THF containing synthetic anticancer drug (WHI-261) was designed for targeting a previously unrecognized unique narrow binding cavity on the surface of tubulin. The anti-cancer activity of WHI-261 was confirmed using MTT assays. The structure-based design, synthesis, and biological activity of WHI-261 are reported.

CiteXplore: 10843205

DOI: 10.1016/s0960-894x(00)00148-7

Patent ID: